Covishield

In his letter to the prime minister, Congress leader Adhir Ranjan Chowdhury claimed that there is a lack of availability of Covaxin and Covishield, and most children below 18 years remain unprotected

Seventy per cent of people who received a booster dose of Covid vaccine did not get infected during the third wave, according to a new study that covered around 6,000 people in India.

Serum Institute of India Ltd., the world's largest vaccine manufacturer and a key supplier of Covid-19 inoculations to developing countries, has stopped making fresh batches of shots after its stockpile grew to 200 million doses amid a global supply

Private hospitals in Tamil Nadu have not slashed the prices of Covid vaccines -- Covishield ad Covaxin -- even though the government has announced a massive reduction.

Serum Institute of India CEO Adar Poonawalla and Bharat Biotech cofounder Suchitra Ella today said that the decision was taken after discussions with the Centre.

The prices of Covishield and Covaxin vaccines at private hospitals have been slashed by more than half. This comes a day before the Covid vaccine booster shots become available to all Indian adults.

Mr Poonawala told NDTV that Covishield will cost Rs 600 plus taxes (same as before) and Covovax, once approved as a booster, will be available for Rs.900 plus taxes.

Neutralising antibody levels waned after six months in those who were fully vaccinated against the coronavirus with Covishield, Covaxin and a mix of both with regard to Omicron variant, a study done by the National Institute of Virology indicated.

India's apex body on immunisation NTAGI has recommended administering the second dose of COVID-19 vaccine Covishield between eight and 16 weeks after the first dose.

The Union Health Ministry today refuted as "misleading" media reports which claimed that 50 lakh unused Covishield doses may go waste by the end of this month.

Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.

India's drug regulator has granted regular market approval for COVID-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said today.

Covaxin and Covishield could be more widely available with a new government approval that also suggests changes in rules for booster doses. Both vaccines have been cleared for "full use" by an expert panel of the central drug authority, a year after

An expert panel of India's central drug authority today recommended granting regular market approval to Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said

A 55-year-old man, who had become paralysed and lost his voice four years ago in an accident, said he was able to move and speak after he was given Covishield vaccine on January 4.

In his letter to the prime minister, Congress leader Adhir Ranjan Chowdhury claimed that there is a lack of availability of Covaxin and Covishield, and most children below 18 years remain unprotected

Seventy per cent of people who received a booster dose of Covid vaccine did not get infected during the third wave, according to a new study that covered around 6,000 people in India.

Serum Institute of India Ltd., the world's largest vaccine manufacturer and a key supplier of Covid-19 inoculations to developing countries, has stopped making fresh batches of shots after its stockpile grew to 200 million doses amid a global supply

Private hospitals in Tamil Nadu have not slashed the prices of Covid vaccines -- Covishield ad Covaxin -- even though the government has announced a massive reduction.

Serum Institute of India CEO Adar Poonawalla and Bharat Biotech cofounder Suchitra Ella today said that the decision was taken after discussions with the Centre.

The prices of Covishield and Covaxin vaccines at private hospitals have been slashed by more than half. This comes a day before the Covid vaccine booster shots become available to all Indian adults.

Mr Poonawala told NDTV that Covishield will cost Rs 600 plus taxes (same as before) and Covovax, once approved as a booster, will be available for Rs.900 plus taxes.

Neutralising antibody levels waned after six months in those who were fully vaccinated against the coronavirus with Covishield, Covaxin and a mix of both with regard to Omicron variant, a study done by the National Institute of Virology indicated.

India's apex body on immunisation NTAGI has recommended administering the second dose of COVID-19 vaccine Covishield between eight and 16 weeks after the first dose.

The Union Health Ministry today refuted as "misleading" media reports which claimed that 50 lakh unused Covishield doses may go waste by the end of this month.

Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.

India's drug regulator has granted regular market approval for COVID-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said today.

Covaxin and Covishield could be more widely available with a new government approval that also suggests changes in rules for booster doses. Both vaccines have been cleared for "full use" by an expert panel of the central drug authority, a year after

An expert panel of India's central drug authority today recommended granting regular market approval to Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said

A 55-year-old man, who had become paralysed and lost his voice four years ago in an accident, said he was able to move and speak after he was given Covishield vaccine on January 4.